Importance COVID-19 is associated with clinically significant symptoms despite resolution
of the acute infection (ie, post-COVID-19 syndrome). Fatigue and cognitive impairment are …

Importance Preexisting noncommunicable diseases (eg, diabetes) increase the risk of
COVID-19 infection, hospitalization, and death. Mood disorders are associated with impaired …

Ketamine is a promising therapeutic option in treatment-resistant depression (TRD). The
acute efficacy of ketamine in TRD has been demonstrated in replicated randomised-controlled …

The prevalence and etiology of COVID-19's impact on brain health and cognitive function is
poorly characterized. With mounting reports of delirium, systemic inflammation, and …

Background With the rise of fragility, conflict and violence (FCV), understanding the prevalence
and risk factors associated with mental disorders is beneficial to direct aid to vulnerable …

Therapeutic deficiencies with monoaminergic antidepressants invites the need to identify
and develop novel rapid-acting antidepressants. Hitherto, ketamine and esketamine are …

Objectives The study herein aimed to assess the prevalence of type 2 diabetes mellitus (T2DM),
impaired fasting glucose (IFG), as well as general and abdominal obesity in patients …

Psychedelics are a hallucinogenic class of psychoactive drugs with the primary effect of
activating non-ordinary states of consciousness. Due to the positive preliminary findings of these …

Hitherto no therapeutic has received regulatory approval for the treatment of post-COVID-19
condition (PCC). Cognitive deficits, mood symptoms and significant reduction in health-…

Glucagon-like peptide 1 (GLP-1) receptor agonists are widely used for glycemic control in
patients with diabetes mellitus (DM) and are primarily indicated for type 2 diabetes mellitus (…